Hirotsu Bio Science

Biological diagnostics deliver a high level of sensitivity by leveraging biology, surpassing the sensitivity of artificial devices, while enabling costs to be kept low by selecting organisms that cost nothing for upkeep. Hirotsu Bio Science is working on the practical use of the world’s first-ever biological diagnosis, a cancer test known as N-NOSE. The test uses urine samples and is therefore non-invasive and simple, combining benefits including high sensitivity, low costs and early detection. It launched the commercial service of N-NOSE in January 2020 in Japan. In 2022, it developed and launched the world’s first pancreatic cancer test using genetic manipulation technology.

Visite el sitio web de Hirotsu Bio Science

Sobre nosostros



Socios y Miembros

  • Únete

Ediciones en otros idiomas

Política de privacidad y normas de uso

© 2024 Foro Económico Mundial